Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Seres Therapeutics, Inc. MCRB

Healthcare  —  Biotechnology
3.52 (0.10) (2.76%) as of 25 Sep
Market cap
$36.0M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Seres Therapeutics, Inc. (MCRB) Business Profile

Updated before January 2025

Company Overview

Seres Therapeutics, Inc. (NASDAQ: MCRB) is a leading biotechnology company focused on developing innovative microbiome therapeutics. Founded in 2010 and headquartered in Cambridge, Massachusetts, Seres Therapeutics is at the forefront of microbiome science, leveraging its expertise to develop novel treatments for a range of diseases. The company was co-founded by Dr. Noubar Afeyan, Dr. David Berry, and Dr. Roger Pomerantz, who envisioned harnessing the power of the human microbiome to address unmet medical needs. Seres Therapeutics is led by a team of seasoned executives, including CEO Eric D. Shaff, who brings extensive experience in biotechnology and corporate strategy. The company’s leadership team also includes Chief Scientific Officer Matthew Henn, Ph.D., and Chief Medical Officer Lisa von Moltke, M.D., who collectively drive the company’s scientific and clinical advancements.

Core Business Segments

Seres Therapeutics operates primarily in the field of microbiome therapeutics, focusing on the development of biologically-derived treatments for diseases linked to dysbiosis, or imbalances in the human microbiome. The company’s core business segments include:

1. Microbiome Therapeutics

Seres Therapeutics develops microbiome-based therapeutics using its proprietary platform. Key products and programs include:

  • SER-109: A first-in-class oral microbiome therapeutic designed to prevent recurrent Clostridioides difficile infection (rCDI). SER-109 has shown promising results in clinical trials and is a cornerstone of the company’s portfolio.
  • SER-155: A therapeutic candidate aimed at reducing infections and improving outcomes in immunocompromised patients, such as those undergoing hematopoietic stem cell transplantation.
  • SER-287: A therapeutic candidate for ulcerative colitis, targeting inflammatory bowel disease (IBD) through microbiome modulation.

2. Research and Development (R&D)

Seres Therapeutics invests heavily in R&D to expand its pipeline of microbiome therapeutics. The company collaborates with academic institutions and industry partners to explore new applications of microbiome science.

3. Strategic Partnerships

The company has established partnerships with leading pharmaceutical companies, such as Nestlé Health Science, to co-develop and commercialize microbiome therapeutics. These collaborations enhance Seres Therapeutics’ ability to bring its products to market and expand its global reach.

Business Model

Seres Therapeutics operates on a business model that integrates cutting-edge research, clinical development, and strategic partnerships to bring microbiome therapeutics to market. The company generates revenue through:

  • Product Sales: Once approved, Seres Therapeutics plans to commercialize its microbiome therapeutics, such as SER-109, to generate revenue.
  • Collaborations and Licensing Agreements: The company receives milestone payments and royalties from partners like Nestlé Health Science for co-development and commercialization efforts.
  • Government Grants and Funding: Seres Therapeutics occasionally secures funding from government agencies to support its research initiatives.

The company’s approach emphasizes innovation, leveraging its proprietary microbiome platform to develop targeted therapies that address significant unmet medical needs.

Strategic Direction

Seres Therapeutics is committed to advancing the field of microbiome therapeutics and expanding its product pipeline. Key strategic priorities include:

  • Regulatory Approvals: The company is focused on securing regulatory approvals for SER-109 and other pipeline candidates to bring its products to market.
  • Pipeline Expansion: Seres Therapeutics aims to develop new microbiome therapeutics for additional indications, such as metabolic disorders and oncology.
  • Global Commercialization: Through partnerships with companies like Nestlé Health Science, Seres Therapeutics plans to expand its global footprint and make its products accessible to patients worldwide.
  • Sustainability Goals: The company is committed to sustainable practices in its research, development, and manufacturing processes, aligning with broader environmental and social responsibility objectives.

Competitive Landscape

Seres Therapeutics operates in a competitive biotechnology sector, facing competition from companies developing microbiome-based therapies and traditional pharmaceutical treatments. Key competitors include:

  • Rebiotix (a Ferring Pharmaceuticals company): Focused on microbiota restoration therapies, including treatments for recurrent C. difficile infection.
  • Vedanta Biosciences: A clinical-stage company developing defined bacterial consortia for various indications.
  • Finch Therapeutics: Specializes in microbiome therapeutics for gastrointestinal diseases.
  • Synthetic Biologics: Develops microbiome-focused therapies for infectious diseases and gastrointestinal disorders.

Despite the competition, Seres Therapeutics differentiates itself through its proprietary platform, robust clinical data, and strategic partnerships.

Risk Factors

Like any biotechnology company, Seres Therapeutics faces several risks, including:

  • Regulatory Risks: Delays or failures in obtaining regulatory approvals for its products could impact the company’s ability to commercialize its therapies.
  • Market Dependence: The company’s success is heavily reliant on the commercial success of its lead product, SER-109.
  • Supply Chain Disruptions: Challenges in sourcing raw materials or manufacturing microbiome therapeutics could affect product availability.
  • Competition: The rapidly evolving microbiome therapeutics landscape presents competitive risks from both established pharmaceutical companies and emerging biotech firms.
  • Financial Risks: As a clinical-stage company, Seres Therapeutics may face challenges in securing sufficient funding to support its operations and pipeline development.

Recent Developments

Seres Therapeutics has made significant progress in recent years, including:

  • SER-109 Clinical Trials: The company reported positive Phase 3 clinical trial results for SER-109, demonstrating its efficacy in preventing recurrent C. difficile infection.
  • Partnership with Nestlé Health Science: Seres Therapeutics expanded its collaboration with Nestlé Health Science to include additional microbiome therapeutic candidates.
  • Pipeline Advancements: The company initiated clinical trials for SER-155 and continued preclinical development of other pipeline candidates.
  • COVID-19 Impact: While the pandemic posed challenges, Seres Therapeutics adapted by implementing remote work policies and maintaining its clinical trial timelines.

Investment Considerations

Investors considering Seres Therapeutics should weigh the following factors:

Strengths:

  • Innovative Platform: Seres Therapeutics’ proprietary microbiome platform positions it as a leader in the field.
  • Strong Pipeline: The company has a robust pipeline of microbiome therapeutics targeting high-value indications.
  • Strategic Partnerships: Collaborations with industry leaders like Nestlé Health Science enhance the company’s commercialization potential.
  • Positive Clinical Data: Promising results from clinical trials, particularly for SER-109, underscore the efficacy of the company’s therapies.

Risks:

  • Regulatory Uncertainty: Delays or failures in obtaining regulatory approvals could impact the company’s growth prospects.
  • Financial Dependence: As a pre-commercial company, Seres Therapeutics relies on external funding to support its operations.
  • Market Competition: The microbiome therapeutics space is highly competitive, with several companies vying for market share.

Conclusion

Seres Therapeutics, Inc. is a pioneering biotechnology company with a strong focus on microbiome therapeutics. With a robust pipeline, strategic partnerships, and a commitment to innovation, the company is well-positioned to address significant unmet medical needs. While challenges remain, such as regulatory and financial risks, Seres Therapeutics’ leadership in the microbiome space and its promising clinical data make it a compelling player in the biotechnology sector. As the company advances its pipeline and expands its global reach, it is poised for long-term growth and success.